- Home
- ACAD vs AZZ Comparison
ACAD vs AZZ Comparison
Compare ACAD & AZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACAD | AZZ |
|---|---|---|
| Founded | 1993 | 1956 |
| Country | US | US |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.3B |
| IPO Year | 2000 | 1994 |
Fundamental Metrics
Financial Performance| Metric | ACAD | AZZ |
|---|---|---|
| Price | $23.30 | $134.53 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 22 | 5 |
| Target Price | $29.95 | ★ $118.00 |
| AVG Volume (30 Days) | ★ 1.2M | 131.5K |
| Earning Date | 04-12-2026 | 04-08-2026 |
| Dividend Yield | N/A | ★ 0.60% |
| EPS Growth | ★ 467.57 | N/A |
| EPS | 0.69 | ★ 9.97 |
| Revenue | $726,437,000.00 | ★ $1,061,817,000.00 |
| Revenue This Year | $15.06 | $5.53 |
| Revenue Next Year | $11.34 | $5.59 |
| P/E Ratio | $33.59 | ★ $13.32 |
| Revenue Growth | ★ 40.45 | 14.53 |
| 52 Week Low | $14.08 | $70.90 |
| 52 Week High | $28.35 | $141.18 |
Technical Indicators
Market Signals| Indicator | ACAD | AZZ |
|---|---|---|
| Relative Strength Index (RSI) | 42.40 | 62.89 |
| Support Level | $21.51 | $131.93 |
| Resistance Level | $26.23 | $141.18 |
| Average True Range (ATR) | 0.84 | 3.65 |
| MACD | -0.07 | -0.05 |
| Stochastic Oscillator | 40.04 | 61.25 |
Price Performance
Historical ComparisonAbout ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
About AZZ AZZ Inc.
AZZ Inc is a provider of galvanizing and a variety of metal coating solutions and coil coating solutions to a broad range of end markets in North America. The company's operating segment consists of Metal Coatings, Precoat Metals, and Infrastructure Solutions. The company generates the majority of its revenue from the Precoat Metals segment, which provides coil coating application of protective and decorative coatings and related value-added downstream processing for steel and aluminum coils. Geographically, the company generates the majority of its revenue from the United States.